Two Peptides, Side by Side

The short version

This page lines up BPC-157 and TB-500 on the dimensions that matter most when reading research peptides: what kind of molecule each one is, where it has been studied most, how strong that evidence is, how it was administered in studies, its regulatory standing, and its single biggest caution. The headline is direct. Both are studied for tissue repair, but they are at different points in the evidence chain: BPC-157 has the deeper animal record plus three tiny human pilots; TB-500's human data largely belongs to a bigger parent protein, not the fragment sold under that name. Neither is an approved medicine, and neither is presented here with a human dose.

The comparison matrix

Peptide class

The two differ significantly in size and origin. BPC-157 is fifteen amino acids — a stable gastric pentadecapeptide drawn from a cytoprotective protein in gastric juice. TB-500 is seven amino acids — a synthetic fragment carrying the actin-binding motif of the much larger thymosin beta-4 protein ^[8]. Despite the size difference, both have been studied primarily for their effects on tissue repair and healing.

Most-studied in

Each peptide has a primary research territory. BPC-157's animal record is broad, spanning tendon, gut, muscle and nerve injury, with the angiogenesis mechanism running throughout ^[4][5]. TB-500's research centers on actin biology and the cell migration and angiogenesis that follow from it, studied across wound, corneal, cardiac and CNS models ^[8][12]. The overlap in angiogenesis as a shared downstream effect is the main mechanistic thread connecting the two.

Evidence base (model)

This is where the two separate most clearly. BPC-157 has decades of animal work and three small uncontrolled human pilots, the most recent being a 2025 two-person IV safety study ^[1][2]. TB-500's strongest human data — a Phase 1 IV safety study in 40 healthy volunteers — used full-length thymosin beta-4, not the marketed fragment; the fragment itself has no completed controlled clinical trials ^[8][9]. Both remain far from the evidence standards required for drug approval.

Administration studied

Routes follow the research questions. BPC-157 has been studied intramuscularly, intragastrically, in drinking water, and in a tiny intravenous human safety pilot, with PK data in rats and dogs ^[3][5]. TB-500 / Tβ4 work used intravenous dosing in the human Phase 1 and intraperitoneal dosing in animal models, including the rat stroke dose-response study ^[7][9].

Regulatory / WADA status

Neither compound is an approved medicine. BPC-157 is prohibited in sport by WADA under the S0 non-approved-substances category ^[2]. TB-500 is also WADA-prohibited (peptide/growth-factor categories), is a prescription medicine in some jurisdictions such as Australia and New Zealand, and has been encountered as a doping agent in racehorses ^[6]. Compounding pharmacies in some markets have been restricted from producing BPC-157 pending further regulatory evaluation.

Key caution

Each carries a defining caveat. For BPC-157 it is that the broad, internally consistent signal lives mostly in rodents from a single research group, with only three tiny human pilots and no large-scale trials ^[2]. For TB-500 it is the identity gap — the marketed fragment is not the molecule behind most of the efficacy data — plus a theoretical tumor-angiogenesis signal from the parent protein's pro-migratory properties ^[8]. Reading them together, the lesson is consistent: mechanistically coherent animal data that has not yet been matched by rigorous human evidence.